Aortic thoracic neuromodulation in heart failure with preserved ejection fraction.
Aortic thoracic neuromodulation
Autonomic imbalance
Enopace
Harmony™ system
Heart failure with preserved ejection fraction (HFpEF)
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
07
08
2022
received:
01
03
2022
accepted:
24
08
2022
pubmed:
25
9
2022
medline:
26
1
2023
entrez:
24
9
2022
Statut:
ppublish
Résumé
The inadequacy of medical therapies for heart failure with preserved ejection fraction (HFpEF) is driving the development of device-based solutions targeting underlying pathophysiologic abnormalities. The maladaptive autonomic imbalance with a reduction in vagal parasympathetic activity and increased sympathetic signalling contributes to the deterioration of cardiac performance, patient fitness, and the increased overall morbidity and mortality. Thoracic aortic vagal afferents mediate parasympathetic signalling, and their stimulation has been postulated to restore autonomic balance. In this first-in-man experience with chronic stimulation of aortic vagal afferents (Harmony™ System, Enopace, Israel), we demonstrate improved left atrial remodelling and function parallel with improved left ventricular performance. The observed favourable structural and functional cardiac changes remained stable throughout the 1 year follow-up and were associated with improved symptoms and physical fitness. The current experience warrants further validation of the endovascular stimulation of aortic thoracic afferents as a new interventional approach for device-based treatment in HFpEF.
Identifiants
pubmed: 36151858
doi: 10.1002/ehf2.14136
pmc: PMC9871658
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-704Subventions
Organisme : CardioPaTh PhD Program
Informations de copyright
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
JACC Cardiovasc Interv. 2022 Feb 14;15(3):321-332
pubmed: 35144789
ESC Heart Fail. 2023 Feb;10(1):699-704
pubmed: 36151858
Front Physiol. 2019 Nov 05;10:1347
pubmed: 31749710
Circulation. 1988 Oct;78(4):969-79
pubmed: 3168199
Hypertension. 2017 May;69(5):836-843
pubmed: 28320856
Eur J Echocardiogr. 2011 Jun;12(6):431-9
pubmed: 21576113
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Circ J. 2013;77(6):1490-8
pubmed: 23446041
ESC Heart Fail. 2022 Feb;9(1):373-384
pubmed: 34821061
Eur J Heart Fail. 2020 Mar;22(3):391-412
pubmed: 32133741
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Circulation. 1997 Jan 7;95(1):90-6
pubmed: 8994422
Cell Rep. 2019 Nov 19;29(8):2192-2201.e3
pubmed: 31747594
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
J Am Coll Cardiol. 2020 Jul 7;76(1):1-13
pubmed: 32616150
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
J Am Coll Cardiol. 2009 Nov 3;54(19):1747-62
pubmed: 19874988
Am J Physiol. 1991 Jul;261(1 Pt 2):H63-9
pubmed: 1858931
JACC Basic Transl Sci. 2021 Aug 04;6(9-10):772-795
pubmed: 34754993
J Am Soc Echocardiogr. 2008 Oct;21(10):1138-44
pubmed: 18926389
Lancet. 2017 Dec 16;390(10113):2655-2661
pubmed: 28870716
J Comp Neurol. 2010 Jul 15;518(14):2771-93
pubmed: 20506475
N Engl J Med. 2006 Jul 20;355(3):251-9
pubmed: 16855265